BioSpace News Archive

Emergent BioSolutions Inc. announced the appointment of Dr. Karen L. Smith, M.D., Ph.D. as chief medical officer with responsibility for leading and further establishing Emergent’s global integrated capability in clinical development, medical affairs, and regulatory affairs.

Company to Host Conference Call on Tuesday, May 5, 2020 at 1:30 p.m. PT / 4:30 p.m. ET

X-Biotix Therapeutics, Inc., announced the appointment of industry veteran, Michael W. Bonney to the company’s Board of Directors.

Mogrify Ltd and Sangamo Therapeutics announced that they have executed a collaboration and exclusive license agreement for Sangamo to develop allogeneic cell therapies from Mogrify’s proprietary induced pluripotent stem cells and embryonic stem cells and Sangamo’s zinc finger protein gene-engineered chimeric antigen receptor regulatory T cell technology.

Mogrify Ltd (Mogrify ® ), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license agreement for Sangamo to develop allogeneic cell therapies from Mogrify’s proprietary induce

Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT ® , its non-invasive and flexible continuous glucose monitor (“CGM”), today announced it has secured a 24-month, $5 million non-convertible loan. The loan does not include warrants or other equity securities.

Dr. Golan, an infectious disease thought leader at Tufts Medical Center, fills key clinical position to help advance Appili’s infectious disease portfolio

Graybug Vision, Inc., a clinical stage biopharmaceutical company focused on developing transformative medicines to treat vision-threatening diseases of the retina and optic nerve, announces that a recent publication of the article ‘Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles’ in Nature Communications was recognized as an Editors’ Highlight by the journal.

Acerus Announces Publication of Results for NATESTO ® Spermatogenesis Study in Journal of Urology

Simplify Medical Pty Ltd., maker of the Simplify® cervical artificial disc, announced the completion of the Pre-Market Approval submission for the 1-level Simplify Disc IDE Study to the U.S. Food and Drug Administration.